Ali Rihani

1.1k total citations
18 papers, 547 citations indexed

About

Ali Rihani is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Ali Rihani has authored 18 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Neurology and 9 papers in Oncology. Recurrent topics in Ali Rihani's work include Neuroblastoma Research and Treatments (9 papers), Cancer-related Molecular Pathways (8 papers) and Molecular Biology Techniques and Applications (4 papers). Ali Rihani is often cited by papers focused on Neuroblastoma Research and Treatments (9 papers), Cancer-related Molecular Pathways (8 papers) and Molecular Biology Techniques and Applications (4 papers). Ali Rihani collaborates with scholars based in Belgium, Sweden and Germany. Ali Rihani's co-authors include Jo Vandesompele, Tom Van Maerken, Frank Speleman, Anne De Paepe, Alan Van Goethem, Jean‐Christophe Marine, Nurten Yigit, Steve Lefever, Gert Van Peer and Pieter Mestdagh and has published in prestigious journals such as PLoS ONE, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Ali Rihani

17 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Rihani Belgium 13 378 204 184 179 50 18 547
Daniel Dreidax Germany 9 308 0.8× 138 0.7× 104 0.6× 185 1.0× 35 0.7× 12 446
Annette Vu United States 6 377 1.0× 219 1.1× 75 0.4× 120 0.7× 30 0.6× 9 503
Ali Syed United States 6 401 1.1× 103 0.5× 186 1.0× 207 1.2× 50 1.0× 11 628
Pooja Pungaliya United States 8 360 1.0× 36 0.2× 142 0.8× 148 0.8× 34 0.7× 8 456
Shih-Ya Wang United States 8 666 1.8× 136 0.7× 203 1.1× 29 0.2× 47 0.9× 9 751
Ilja Roobeek Netherlands 9 531 1.4× 78 0.4× 68 0.4× 112 0.6× 44 0.9× 10 678
You-Chin Lin Taiwan 9 417 1.1× 298 1.5× 42 0.2× 52 0.3× 30 0.6× 10 515
Hélène Dumay‐Odelot France 13 774 2.0× 110 0.5× 120 0.7× 28 0.2× 53 1.1× 16 858
Rahul Reddy United States 4 625 1.7× 459 2.3× 122 0.7× 21 0.1× 36 0.7× 4 773
T. Crnogorac-Jurcevic United Kingdom 7 225 0.6× 66 0.3× 126 0.7× 27 0.2× 34 0.7× 7 394

Countries citing papers authored by Ali Rihani

Since Specialization
Citations

This map shows the geographic impact of Ali Rihani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Rihani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Rihani more than expected).

Fields of papers citing papers by Ali Rihani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Rihani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Rihani. The network helps show where Ali Rihani may publish in the future.

Co-authorship network of co-authors of Ali Rihani

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Rihani. A scholar is included among the top collaborators of Ali Rihani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Rihani. Ali Rihani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Aguilera, Katherina, Ulrika Marking, Nina Greilert‐Norin, et al.. (2024). Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023. The Lancet Regional Health - Europe. 38. 100872–100872.
2.
Peuget, Sylvain, Jiawei Zhu, Gema Sanz, et al.. (2020). Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds. Cancer Research. 80(7). 1538–1550. 14 indexed citations
3.
Singh, Madhurendra, Xiaolei Zhou, Xinsong Chen, et al.. (2020). Identification and targeting of selective vulnerability rendered by tamoxifen resistance. Breast Cancer Research. 22(1). 10 indexed citations
4.
Lefever, Steve, Ali Rihani, Joni Van der Meulen, et al.. (2019). Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR. Scientific Reports. 9(1). 2150–2150. 30 indexed citations
5.
Renard, Marjolijn, Suzanne Vanhauwaert, Ali Rihani, et al.. (2018). Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice. Scientific Reports. 8(1). 7642–7642. 10 indexed citations
6.
Rihani, Ali, Jo Vandesompele, Frank Speleman, & Tom Van Maerken. (2015). Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell International. 15(1). 76–76. 37 indexed citations
7.
Rihani, Ali, Alan Van Goethem, Maté Ongenaert, et al.. (2015). Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. Scientific Reports. 5(1). 9027–9027. 31 indexed citations
8.
Rihani, Ali, Bram De Wilde, Geneviève Laureys, et al.. (2014). CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. PLoS ONE. 9(12). e114696–e114696. 19 indexed citations
9.
Vanhauwaert, Suzanne, Gert Van Peer, Ali Rihani, et al.. (2014). Expressed Repeat Elements Improve RT-qPCR Normalization across a Wide Range of Zebrafish Gene Expression Studies. PLoS ONE. 9(10). e109091–e109091. 37 indexed citations
10.
Rihani, Ali, Tom Van Maerken, Bram De Wilde, et al.. (2014). Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatric Blood & Cancer. 61(10). 1867–1870. 3 indexed citations
11.
Peer, Gert Van, Steve Lefever, Jasper Anckaert, et al.. (2014). miRBase Tracker: keeping track of microRNA annotation changes. Database. 2014. 69 indexed citations
12.
Rihani, Ali, Tom Van Maerken, Filip Pattyn, et al.. (2013). Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments. PLoS ONE. 8(8). e71776–e71776. 12 indexed citations
13.
Maerken, Tom Van, Ali Rihani, Alan Van Goethem, et al.. (2013). Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Cancer Letters. 344(2). 157–165. 36 indexed citations
14.
Maerken, Tom Van, Ali Rihani, Alan Van Goethem, et al.. (2013). Selective inhibition of the p53–MDM2 interaction by nutlin drugs: a new therapeutic perspective for neuroblastoma. Ghent University Academic Bibliography (Ghent University). 2. 198–207. 1 indexed citations
15.
Maerken, Tom Van, Ali Rihani, Daniel Dreidax, et al.. (2011). Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3. Molecular Cancer Therapeutics. 10(6). 983–993. 61 indexed citations
16.
Vergult, Sarah, Andrew Dauber, Barbara Delle Chiaie, et al.. (2011). 17q24.2 microdeletions: a new syndromal entity with intellectual disability, truncal obesity, mood swings and hallucinations. European Journal of Human Genetics. 20(5). 534–539. 27 indexed citations
17.
Maerken, Tom Van, Liesbeth Ferdinande, Irina Lambertz, et al.. (2009). Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53. JNCI Journal of the National Cancer Institute. 101(22). 1562–1574. 99 indexed citations
18.
Maerken, Tom Van, Jo Vandesompele, Ali Rihani, Anne De Paepe, & Frank Speleman. (2009). Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis. Cell Death and Differentiation. 16(12). 1563–1572. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Dreidax Breakdown of academic impact, for papers by Annette Vu Breakdown of academic impact, for papers by Ali Syed Breakdown of academic impact, for papers by Pooja Pungaliya Breakdown of academic impact, for papers by Shih-Ya Wang Breakdown of academic impact, for papers by Ilja Roobeek Breakdown of academic impact, for papers by You-Chin Lin Breakdown of academic impact, for papers by Hélène Dumay‐Odelot Breakdown of academic impact, for papers by Rahul Reddy Breakdown of academic impact, for papers by T. Crnogorac-Jurcevic
Rankless by CCL
2026